51380-85-9

Upstream product

• 108-88-3 toluene 
• 356535-58-5 5-(2-p-tolylpropane)-(2,2)-dimethyl-(1,3)-dioxane-4,6-dione 
• 872791-94-1 (1-methyl-1-p-tolyl-ethyl)-malonic acid 
• 2231-66-5 2,2-dimethyl-5-(propan-2-ylidene)-1,3-dioxane-4,6-dione 
• 42288-08-4 3-methyl-3-p-tolyl-butyric acid 

Downstream Products

• 54484-71-8 3,3,6-Trimethyl-1-indanone 
• 3990-84-9 β-p-Tolyl-perisovaleriansaeure-tert-butylester 
• 27724-60-3 3-Methyl-3-(p-tolyl)-1-butanol⁽²⁾ 
• 858214-23-0 3-methyl-3-p-tolyl-butyraldehyde 
• 88893-05-4 β-p-Tolyl-valeriansaeure-anilid 
• 94913-70-9 β-p-Tolyl-valeriansaeure-benzylamid 
• 54290-36-7 1-Chlor-3-methyl-3-p-tolylbutan 
• 14656-06-5 1,1,3,5,-tetramethyl-indene 

Relevant academic research and scientific papers

A regiospecific synthesis of 3,3,6-trimethylindan-1-one

A novel, regiospecific synthesis of 3,3,6-trimethylindan1-one (5) was achieved. The route to 5 was 6 steps and proceeded in 27% overall yield.

Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH)

Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppressi